You have read all your free articles, to continue reading subscribe to read the rest of this content.
The companies have announced data on the drug candidate lecanemab (BAN2401). The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down’s syndrome with signs of functional or cognitive deterioration. Preliminary results presented from the onAlready a subscriber Login You have read all your free…
Saniona announced July 26th that the U.S. Food and Drug Administration had granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation, the company states. Saniona iAlready a subscriber Login You have…
Finnish Industry Investment half-year report 2016 shows a record-high investment volume – €100 million to finance company growth. “Our investment volume in the first half of 2016 was record-high: we made new investments and commitments amounting to over €100 million. Significant events inAlready a subscriber Login You have read all…
Cantargia announces that the company has received an Intention to Grant notice from the European Patent Office for its patent application for the CAN04 product candidate. The patent application, with application number 15714603.6, for which the EPO has issued an Intention to Grant notice, refers Already a subscriber Login You…
